LMT503 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05659953 (ClinicalTrials.gov) | March 1, 2023 | 25/11/2022 | LMT503 First-in-human SAD, MAD, and FE Study | A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LMT503 in Healthy Subjects | Colitis, Ulcerative;Crohn Disease;Inflammatory Bowel Disease | Drug: LMT503;Drug: Placebo | Lmito Therapeutics Inc. | NULL | Not yet recruiting | 18 Years | 65 Years | All | 72 | Phase 1 | Netherlands |